Allele-specific collateral and fitness effects determine the dynamics of fluoroquinolone resistance evolution.
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
03 05 2022
03 05 2022
Historique:
entrez:
27
4
2022
pubmed:
28
4
2022
medline:
30
4
2022
Statut:
ppublish
Résumé
Collateral sensitivity (CS), which arises when resistance to one antibiotic increases sensitivity toward other antibiotics, offers treatment opportunities to constrain or reverse the evolution of antibiotic resistance. The applicability of CS-informed treatments remains uncertain, in part because we lack an understanding of the generality of CS effects for different resistance mutations, singly or in combination. Here, we address this issue in the gram-positive pathogen Streptococcus pneumoniae by measuring collateral and fitness effects of clinically relevant gyrA and parC alleles and their combinations that confer resistance to fluoroquinolones. We integrated these results in a mathematical model that allowed us to evaluate how different in silico combination treatments impact the dynamics of resistance evolution. We identified common and conserved CS effects of different gyrA and parC alleles; however, the spectrum of collateral effects was unique for each allele or allelic pair. This indicated that allelic identity can impact the evolutionary dynamics of resistance evolution during monotreatment and combination treatment. Our model simulations, which included the experimentally derived antibiotic susceptibilities and fitness effects, and antibiotic-specific pharmacodynamics revealed that both collateral and fitness effects impact the population dynamics of resistance evolution. Overall, we provide evidence that allelic identity and interactions can have a pronounced impact on collateral effects to different antibiotics and suggest that these need to be considered in models examining CS-based therapies.
Identifiants
pubmed: 35476512
doi: 10.1073/pnas.2121768119
pmc: PMC9170170
doi:
Substances chimiques
Anti-Bacterial Agents
0
Fluoroquinolones
0
Banques de données
Dryad
['10.5061/dryad.c2fqz61b4']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2121768119Références
Nat Commun. 2014 Jul 08;5:4352
pubmed: 25000950
PLoS Biol. 2019 Oct 25;17(10):e3000515
pubmed: 31652256
J Pharm Health Care Sci. 2016 Apr 05;2:9
pubmed: 27051524
Annu Rev Microbiol. 2017 Sep 8;71:579-596
pubmed: 28697667
Nat Commun. 2021 Sep 28;12(1):5691
pubmed: 34584086
PLoS Pathog. 2014 Mar 20;10(3):e1004026
pubmed: 24651834
Nat Rev Microbiol. 2011 Nov 02;9(12):894-6
pubmed: 22048738
Antimicrob Agents Chemother. 1995 Jun;39(6):1253-8
pubmed: 7574511
Antimicrob Agents Chemother. 2000 Jul;44(7):1771-7
pubmed: 10858329
Expert Rev Anti Infect Ther. 2008 Oct;6(5):619-35
pubmed: 18847402
Mol Biol Evol. 2017 Sep 1;34(9):2229-2244
pubmed: 28541480
Can J Infect Dis. 1999 May;10(3):207-38
pubmed: 22346384
Elife. 2019 Sep 13;8:
pubmed: 31516122
Antimicrob Agents Chemother. 2007 Sep;51(9):3225-9
pubmed: 17664329
Trends Microbiol. 2014 Aug;22(8):438-45
pubmed: 24842194
Exp Gerontol. 2014 Sep;57:107-13
pubmed: 24862289
Acta Pathol Microbiol Immunol Scand B. 1987 Jun;95(3):159-65
pubmed: 3630711
mBio. 2013 Jul 23;4(4):
pubmed: 23882012
Antimicrob Agents Chemother. 2006 Jan;50(1):269-78
pubmed: 16377697
Clin Microbiol Rev. 2016 Jul;29(3):525-52
pubmed: 27076637
Braz J Microbiol. 2017 Apr - Jun;48(2):225-231
pubmed: 28011228
J Antibiot (Tokyo). 2020 Jun;73(6):329-364
pubmed: 32152527
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Dec 15;1039:74-78
pubmed: 27825625
Antimicrob Agents Chemother. 2007 Feb;51(2):412-6
pubmed: 17116668
Antimicrob Agents Chemother. 2004 Oct;48(10):3670-6
pubmed: 15388418
ISME J. 2013 Apr;7(4):791-9
pubmed: 23303370
J Antimicrob Chemother. 1996 Jan;37(1):77-84
pubmed: 8647777
Science. 2016 Jan 1;351(6268):aad3292
pubmed: 26722002
Nat Commun. 2018 Sep 10;9(1):3673
pubmed: 30202004
Sci Transl Med. 2013 Sep 25;5(204):204ra132
pubmed: 24068739
Antimicrob Agents Chemother. 1994 Sep;38(9):2065-72
pubmed: 7811020
J Bacteriol. 1952 Oct;64(4):489-99
pubmed: 12999676
Cell. 2018 Jan 11;172(1-2):121-134.e14
pubmed: 29307490
Antimicrob Agents Chemother. 2011 Oct;55(10):4619-30
pubmed: 21807983
Mol Biol Evol. 2017 May 1;34(5):1029-1039
pubmed: 28087782
Antimicrob Agents Chemother. 1996 Dec;40(12):2760-4
pubmed: 9124836
Biophys Rev. 2016 Sep;8(3):221-231
pubmed: 27942270
Mol Syst Biol. 2013 Oct 29;9:700
pubmed: 24169403
Front Microbiol. 2017 Jul 31;8:1447
pubmed: 28824578
Evol Med Public Health. 2016 Jun 14;2016(1):182-94
pubmed: 27193199
Antimicrob Agents Chemother. 2011 May;55(5):1867-73
pubmed: 21357301
Biotechnology. 1991;15:173-92
pubmed: 2009380
Gigascience. 2017 May 1;6(5):1-9
pubmed: 28379488
J Antimicrob Chemother. 2003 Sep;52(3):511-3
pubmed: 12888600
Antimicrob Agents Chemother. 2007 Apr;51(4):1191-201
pubmed: 17261623
Int Microbiol. 2021 Nov;24(4):499-506
pubmed: 34028624
Methods Mol Biol. 2014;1151:165-88
pubmed: 24838886